Artificial intelligence tool for predicting prostate cancer from scans and tissue slides
Tests whether artificial intelligence can read MRI and tissue slides to predict prostate cancer.
Plain-language title generated from the registry record
Registry title: Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer
Key facts
- Where
- Nanjing, ChinaSee the site
Where in China
- The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital)Nanjing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shao Pengfei
- Trial code
- NCT06662708
- Record updated
- 29 October 2024
- Original description
The aim of this clinical trial is whether artificial intelligence models can be used for accurate clinical preoperative diagnosis and postoperative diagnosis of pathological findings, and will also measure the accuracy of the predictions made by the artificial intelligence models.The main target questions addressed by the model building are:Read full original descriptionShow less
Accurate Prediction and Treatment of Prostate Cancer by Artificial Intelligence Model-based Whole Slide Images and MRIs
The aim of this clinical trial is whether artificial intelligence models can be used for accurate clinical preoperative diagnosis and postoperative diagnosis of pathological findings, and will also measure the accuracy of the predictions made by the artificial intelligence models.The main target questions addressed by the model building are:
1. whether the AI model can learn from preoperative MRI and postoperative Whole Slide Images so as to accurately predict information such as benignness or malignancy, aggressiveness, grading, subtypes, genes, etc. for participants suspected of having prostate cancer preoperatively/puncturally. 2. whether the AI model is capable of learning postoperative macropathology slides to enable outcome diagnosis of surgical pathology slides in new participants.
Participants will:
1. complete an MRI examination and have their MRI images analysed by the established AI model to make an accurate diagnosis of them. 2. Based on the diagnosis, if prostate cancer is predicted, they will undergo radical prostate cancer surgery and refine their surgical pathology.
Inclusion: Patients with suspected PCa (elevated PSA or suspicious positive lesions on ultrasound or MRI results).
Exclusion: Previous treatment of the prostate in any form, including surgery, radiotherapy/chemotherapy, endocrine therapy, targeted therapy and immunotherapy; Patients with a history of other malignancies, serious comorbidities or other health problems; Patients with any item missing from the baseline clinical and pathological information; Unable to provide/sign an informed consent form; Patients who, in the judgement of the investigator, are deemed unfit to participate in this clinical trial.